Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 40

Sort by

Sort Order Select

Journal Articles

JALSG Ph (-) B-ALL213 Study: Pediatric-Type Chemotherapy Improves Prognosis in Adult Ph-Negative Acute Lymphoblastic Leukemia Patients, Including Older Adults

Blood (2024) 144 (Supplement 1): 2819.

https://doi.org/10.1182/blood-2024-199435

Published: 2024

Journal Articles

Suppression of Super-Enhancer-Driven TAL1 Expression By KLF4 in T-Cell Acute Lymphoblastic Leukemia

Mina Noura, Takahiko Yasuda, Shinobu Tsuzuki, Hidemasa Matsuo, Hitoshi Kiyoi, Fumihiko Hayakawa

Blood (2023) 142 (Supplement 1): 1405.

https://doi.org/10.1182/blood-2023-173640

Published: 2023

Journal Articles

Real-World Data in a Prospective Clinical Observation Study for Newly Diagnosed Adult Acute Lymphoblastic Leukemia, the JALSG ALL-CS-12 : Advanced Age Is a Poor Prognostic Factor

Yoshihiro Hatta, Fumihiko Hayakawa, Etsuko Yamazaki, Tohru Murayama, Takeshi Saito, Satoru Takada, Nobuaki Dobashi, Shuichi Ota, Yasuhisa Yokoyama, Masatsugu Tanaka, Shinya Sato, Shigeki Ohtake, Emiko Sakaida, Yoshinobu Maeda, Takahiro Yamauchi, Itaru Matsumura, Yasushi Miyazaki, Hitoshi Kiyoi

Blood (2023) 142 (Supplement 1): 4199.

https://doi.org/10.1182/blood-2023-178332

Published: 2023

Journal Articles

Risk Stratified Therapy with Nelarabine and Intensified Administration of L-Asparaginase for Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia in Adolescents and Young Adults (JPLSG T-11/JALSG T-ALL-211-U): An Intergroup Phase 2 Study

Blood (2022) 140 (Supplement 1): 124–126.

https://doi.org/10.1182/blood-2022-156613

Published: 2022

Journal Articles

Two novel high-risk adult B-cell acute lymphoblastic leukemia subtypes with high expression of CDX2 and IDH1/2 mutations

Blood (2022) 139 (12): 1850–1862.

https://doi.org/10.1182/blood.2021011921

Published: 2022

Includes: Supplemental data

Journal Articles

Dasatinib-Based Two-Step Induction Prior to Allogeneic Hematopoietic Cell Transplantation for Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: Results of the JALSG Ph+ALL213 Study

Blood (2019) 134 (Supplement_1): 743.

https://doi.org/10.1182/blood-2019-123382

Published: 2019

Journal Articles

The Optimal Treatment Strategy for Adult Patients with Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia in First Complete Remission in the Era of High-Intensity Chemotherapy

Blood (2019) 134 (Supplement_1): 4589.

https://doi.org/10.1182/blood-2019-126012

Published: 2019

Journal Articles

Staurosporine Induces Caspase-Dependent Proteolysis of MEF2D-Fusion Protein and Cell Death Selective to MEF2D-Fusion-Positive ALL Cells

Naoyuki Tange, MD, Fumihiko Hayakawa, MD, PhD, Takahiko Yasuda, MD, PhD, Hideyuki Yamamoto, MD, Daiki Hirano, MD, PhD, Shinobu Tsuzuki, MD,PhD, Hitoshi Kiyoi, MD PhD

Blood (2019) 134 (Supplement_1): 1349.

https://doi.org/10.1182/blood-2019-123602

Published: 2019

Journal Articles

Genomic and Clinical Characterization of Adult Ph-Negative B-Cell Acute Lymphoblastic Leukemia

Takahiko Yasuda, MD, PhD, Dai Nishijima, PhD, Shinya Kojima, PhD, Masahito Kawazu, MD, PhD, Toshihide Ueno, PhD, Shinobu Tsuzuki, MD PhD, Hitoshi Kiyoi, MD PhD, Itaru Matsumura, MD, Yasushi Miyazaki, MD PhD, Keizo Horibe, MD PhD, Hiroyuki Mano, MD, PhD, Tomoki Naoe, MD PhD, Masashi Sanada, MD PhD, Fumihiko Hayakawa, MD, PhD

Blood (2018) 132 (Supplement 1): 2821.

https://doi.org/10.1182/blood-2018-99-115716

Published: 2018

Journal Articles

A Novel PAX5-KIDINS220 Fusion Protein Activates Multiple Signals Associated with Therapeutic Resistance

Takuyo Kanayama, MD, Toshihiko Imamura, MD PhD, Kenichi Sakamoto, MD PhD, Fumihiko Hayakawa, MD, PhD, Akihiko Tanizawa, MD PhD, Nobutaka Kiyokawa, MD PhD, Hajime Hosoi, MD PhD

Blood (2018) 132 (Supplement 1): 3928.

https://doi.org/10.1182/blood-2018-99-116022

Published: 2018

Journal Articles

Exosomes Derived from Cancer Associated Fibroblasts Elicit Survival and Drug Resistance of Primary Lymphoma Cells

Shunsuke Kunou, Kazuyuki Shimada, MD PhD, Tomoya Hikita, PhD, Tomohiro Aoki, MD PhD, Akihiko Sakamoto, PhD, Fumihiko Hayakawa, MD, PhD, Chitose Oneyama, PhD, Hitoshi Kiyoi, MD PhD

Blood (2018) 132 (Supplement 1): 4128.

https://doi.org/10.1182/blood-2018-99-111863

Published: 2018

Journal Articles

ZNF384-Fusion Proteins Have High Affinity to EP300, Which Increases Their Transcriptional Activities

Hideyuki Yamamoto, MD, Fumihiko Hayakawa, MD, PhD, Takahiko Yasuda, MD, PhD, Yuka Minamikawa, Naoyuki Tange, MD, Daiki Hirano, MD, Yuki Kojima, MD, PhD, Takanobu Morishita, MD, PhD, Shinobu Tsuzuki, MD, PhD, Hiroyuki Mano, MD,PhD, Tomoki Naoe, MD PhD, Hitoshi Kiyoi, MD PhD

Blood (2018) 132 (Supplement 1): 1554.

https://doi.org/10.1182/blood-2018-99-114414

Published: 2018

Journal Articles

Biology and management of primary effusion lymphoma

Kazuyuki Shimada, Fumihiko Hayakawa, Hitoshi Kiyoi

Blood (2018) 132 (18): 1879–1888.

https://doi.org/10.1182/blood-2018-03-791426

Published: 2018

Journal Articles

A novel irreversible FLT3 inhibitor, FF-10101, shows excellent efficacy against AML cells with FLT3 mutations

Blood (2018) 131 (4): 426–438.

https://doi.org/10.1182/blood-2017-05-786657

Published: 2018

Includes: Supplemental data

Journal Articles

High Expression of MEF2D-Fusion Protein Is Caused By Escaping from the Suppression By miRNA and Leads to Suppress Transcriptional Activity of PAX5

Hirano Daiki, MD, Fumihiko Hayakawa, MD PhD, Takahiko Yasuda, MDPhD, Naoyuki Tange, MD, Hideyuki Yamamoto, MD, Yuki Kojima, MD PhD, Takanobu Morishita, MD PhD, Naoto Imoto, MD PhD, Shinobu Tsuzuki, MDPhD, Hiroyuki Mano, MDPhD, Tomoki Naoe, MD PhD, Hitoshi Kiyoi, MD PhD

Blood (2017) 130 (Supplement 1): 3977.

https://doi.org/10.1182/blood.V130.Suppl_1.3977.3977

Published: 2017

Journal Articles

YM155 Induces Apoptosis through Proteasome-Dependent Degradation of MCL-1 in Primary Effusion Lymphoma

Yuki Kojima, MD, Fumihiko Hayakawa, MD PhD, Takanobu Morishita, MD, Keiki Sugimoto, PhD, Mizuho Iwase, Hideyuki Yamamoto, MD, Daiki Hirano, MD, Naoto Imoto, MD, Seiji Okada, MD, PhD, Hitoshi Kiyoi, MD PhD

Blood (2016) 128 (22): 3013.

https://doi.org/10.1182/blood.V128.22.3013.3013

Published: 2016

Journal Articles

Emetine Elicits Apoptosis of Intractable B-Cell Lymphoma Cells with MYC Rearrangement through Inhibition of Glycolytic Metabolism

Tomohiro Aoki, MD, Kazuyuki Shimada, MD PhD, Akihiko Sakamoto, PhD, Keiki Sugimoto, PhD, Takanobu Morishita, MD, Yuki Kojima, MD, Satoko Shimada, MD PhD, Seiichi Kato, MD PhD, Chisako Iriyama, MD PhD, Shunsuke Kuno, MD, Yasuhiko Harada, MD, Shigeo Nakamura, MD PhD, Akihiro Tomita, MD PhD, Fumihiko Hayakawa, MD PhD, Hitoshi Kiyoi, MD PhD

Blood (2016) 128 (22): 3019.

https://doi.org/10.1182/blood.V128.22.3019.3019

Published: 2016

Journal Articles

Development of FF-10101, a Novel Irreversible FLT3 Inhibitor, Which Overcomes Drug Resistance Mutations

Toshiyuki Nakatani, PhD, Ken Uda, Takeshi Yamaura, Masaru Takasaki, Akimi Akashi, Fangli Chen, MD, Yuichi Ishikawa, MDPhD, Fumihiko Hayakawa, MD PhD, Shinji Hagiwara, PhD, Hitoshi Kiyoi, MD PhD, Tomoki Naoe, MD PhD

Blood (2015) 126 (23): 1353.

https://doi.org/10.1182/blood.V126.23.1353.1353

Published: 2015

Journal Articles

A Photosensitizer Verteporfin Has Light-Independent Anti-Leukemic Activity for Ph-Positive Acute Lymphoblastic Leukemia and Synergistically Works with Dasatinib in Vivo

Takanobu Morishita, MD, Fumihiko Hayakawa, MD PhD, Keiki Sugimoto, PhD, Daiki Hirano, MD, Yuki Kojima, MD, Naoto Imoto, MD, Yuichiro Inagaki, MD, Tomoki Naoe, MDPhD, Hitoshi Kiyoi, MD PhD

Blood (2015) 126 (23): 1331.

https://doi.org/10.1182/blood.V126.23.1331.1331

Published: 2015

Journal Articles

Effectiveness of High-Dose MTX Therapy for Adult Ph-Negative ALL By Randomized Trial: JALSG ALL202-O

Toru Sakura, Fumihiko Hayakawa, MD PhD, Isamu Sugiura, MD PhD, Kiyotoshi Imai, MD PhD, Noriko Usui, MD, Shin Fujisawa, MD, Tohru Murayama, Toshiaki Yujiri, MD PhD, Hitoshi Kiyoi, MD PhD, Kazunori Ohnishi, MD PhD, Yasushi Miyazaki, MD, Shigeki Ohtake, MD PhD, Yukio Kobayashi, MD PhD, Keitaro Matsuo, MDPhD, Tomoki Naoe, MD PhD

Blood (2015) 126 (23): 79.

https://doi.org/10.1182/blood.V126.23.79.79

Published: 2015

NARROW

JALSG Ph (-) B-ALL213 Study: Pediatric-Type Chemotherapy Improves Prognosis in Adult Ph-Negative Acute Lymphoblastic Leukemia Patients, Including Older Adults

Suppression of Super-Enhancer-Driven TAL1 Expression By KLF4 in T-Cell Acute Lymphoblastic Leukemia

Real-World Data in a Prospective Clinical Observation Study for Newly Diagnosed Adult Acute Lymphoblastic Leukemia, the JALSG ALL-CS-12 : Advanced Age Is a Poor Prognostic Factor

Risk Stratified Therapy with Nelarabine and Intensified Administration of L-Asparaginase for Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia in Adolescents and Young Adults (JPLSG T-11/JALSG T-ALL-211-U): An Intergroup Phase 2 Study

Two novel high-risk adult B-cell acute lymphoblastic leukemia subtypes with high expression of CDX2 and IDH1/2 mutations

Dasatinib-Based Two-Step Induction Prior to Allogeneic Hematopoietic Cell Transplantation for Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: Results of the JALSG Ph+ALL213 Study

The Optimal Treatment Strategy for Adult Patients with Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia in First Complete Remission in the Era of High-Intensity Chemotherapy

Staurosporine Induces Caspase-Dependent Proteolysis of MEF2D-Fusion Protein and Cell Death Selective to MEF2D-Fusion-Positive ALL Cells

Genomic and Clinical Characterization of Adult Ph-Negative B-Cell Acute Lymphoblastic Leukemia

A Novel PAX5-KIDINS220 Fusion Protein Activates Multiple Signals Associated with Therapeutic Resistance

Exosomes Derived from Cancer Associated Fibroblasts Elicit Survival and Drug Resistance of Primary Lymphoma Cells

ZNF384-Fusion Proteins Have High Affinity to EP300, Which Increases Their Transcriptional Activities

Biology and management of primary effusion lymphoma

A novel irreversible FLT3 inhibitor, FF-10101, shows excellent efficacy against AML cells with FLT3 mutations

High Expression of MEF2D-Fusion Protein Is Caused By Escaping from the Suppression By miRNA and Leads to Suppress Transcriptional Activity of PAX5

YM155 Induces Apoptosis through Proteasome-Dependent Degradation of MCL-1 in Primary Effusion Lymphoma

Emetine Elicits Apoptosis of Intractable B-Cell Lymphoma Cells with MYC Rearrangement through Inhibition of Glycolytic Metabolism

Development of FF-10101, a Novel Irreversible FLT3 Inhibitor, Which Overcomes Drug Resistance Mutations

A Photosensitizer Verteporfin Has Light-Independent Anti-Leukemic Activity for Ph-Positive Acute Lymphoblastic Leukemia and Synergistically Works with Dasatinib in Vivo

Effectiveness of High-Dose MTX Therapy for Adult Ph-Negative ALL By Randomized Trial: JALSG ALL202-O

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only